Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.

Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O.

Nature. 2008 Oct 16;455(7215):967-70. doi: 10.1038/nature07398.

PMID:
18923523
2.

Oncogenic mutations of ALK in neuroblastoma.

Ogawa S, Takita J, Sanada M, Hayashi Y.

Cancer Sci. 2011 Feb;102(2):302-8. doi: 10.1111/j.1349-7006.2010.01825.x. Review.

3.

The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.

Kelleher FC, McDermott R.

Eur J Cancer. 2010 Sep;46(13):2357-68. doi: 10.1016/j.ejca.2010.04.006. Epub 2010 May 5. Review.

PMID:
20451371
4.
5.

Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma.

Bourdeaut F, Trochet D, Janoueix-Lerosey I, Ribeiro A, Deville A, Coz C, Michiels JF, Lyonnet S, Amiel J, Delattre O.

Cancer Lett. 2005 Oct 18;228(1-2):51-8. Review.

PMID:
15949893
6.

Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma.

Deyell RJ, Attiyeh EF.

Cancer Genet. 2011 Mar;204(3):113-21. doi: 10.1016/j.cancergen.2011.03.001. Review.

PMID:
21504710
7.

[Oncogenic mutations of ALK are associated with tumorigenesis of neuroblastoma].

Takita J, Ogawa S.

Tanpakushitsu Kakusan Koso. 2009 May;54(6):742-7. Review. Japanese. No abstract available.

PMID:
19462760
8.

Genetics and genomics of neuroblastoma.

Capasso M, Diskin SJ.

Cancer Treat Res. 2010;155:65-84. doi: 10.1007/978-1-4419-6033-7_4. Review.

PMID:
20517688
9.

Global genomic and RNA profiles for novel risk stratification of neuroblastoma.

Ohira M, Nakagawara A.

Cancer Sci. 2010 Nov;101(11):2295-301. doi: 10.1111/j.1349-7006.2010.01681.x. Review.

10.

Emerging importance of ALK in neuroblastoma.

Azarova AM, Gautam G, George RE.

Semin Cancer Biol. 2011 Oct;21(4):267-75. doi: 10.1016/j.semcancer.2011.09.005. Epub 2011 Sep 16. Review.

11.

Inhibitors of anaplastic lymphoma kinase: a patent review.

Milkiewicz KL, Ott GR.

Expert Opin Ther Pat. 2010 Dec;20(12):1653-81. doi: 10.1517/13543776.2010.527332. Epub 2010 Oct 20. Review.

PMID:
20961208
12.

Targeted Therapy for Neuroblastoma: ALK Inhibitors.

Schulte JH, Schulte S, Heukamp LC, Astrahantseff K, Stephan H, Fischer M, Schramm A, Eggert A.

Klin Padiatr. 2013 Nov;225(6):303-8. doi: 10.1055/s-0033-1357132. Epub 2013 Oct 28. Review.

PMID:
24166094
13.

Development of treatment strategies for advanced neuroblastoma.

Hara J.

Int J Clin Oncol. 2012 Jun;17(3):196-203. doi: 10.1007/s10147-012-0417-5. Epub 2012 May 16. Review.

PMID:
22588779
14.

Molecular pathogenesis of peripheral neuroblastic tumors.

Janoueix-Lerosey I, Schleiermacher G, Delattre O.

Oncogene. 2010 Mar 18;29(11):1566-79. doi: 10.1038/onc.2009.518. Epub 2010 Jan 25. Review.

PMID:
20101209
15.

Genetic susceptibility to neuroblastoma.

Tolbert VP, Coggins GE, Maris JM.

Curr Opin Genet Dev. 2017 Feb;42:81-90. doi: 10.1016/j.gde.2017.03.008. Epub 2017 Apr 28. Review.

PMID:
28458126
16.

Recent insights into the biology of neuroblastoma.

Schleiermacher G, Janoueix-Lerosey I, Delattre O.

Int J Cancer. 2014 Nov 15;135(10):2249-61. doi: 10.1002/ijc.29077. Epub 2014 Aug 14. Review.

17.
18.

Neonatal neuroblastoma.

Fisher JP, Tweddle DA.

Semin Fetal Neonatal Med. 2012 Aug;17(4):207-15. doi: 10.1016/j.siny.2012.05.002. Epub 2012 Jun 4. Review.

PMID:
22673527
19.

[Genetic alterations in neuroblastoma and their usefulness for clinical management].

Normand C, Michon J, Janoueix-Lerosey I, Delattre O, Schleiermacher G.

Bull Cancer. 2011 May;98(5):477-88. doi: 10.1684/bdc.2011.1364. Review. French.

20.

Neuroblastoma and Its Zebrafish Model.

Zhu S, Thomas Look A.

Adv Exp Med Biol. 2016;916:451-78. doi: 10.1007/978-3-319-30654-4_20. Review.

PMID:
27165366

Supplemental Content

Support Center